Silence Therapeutics plc (SLN)
| Market Cap | 1.19B +245.4% |
| Revenue (ttm) | 615,000 -97.7% |
| Net Income | -59.95M |
| EPS | -3.81 |
| Shares Out | 60.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,488,216 |
| Open | 19.75 |
| Previous Close | 19.78 |
| Day's Range | 19.71 - 19.80 |
| 52-Week Range | 4.19 - 19.87 |
| Beta | 1.45 |
| Analysts | Hold |
| Price Target | 19.75 (-0.15%) |
| Est. Earnings | Nov 9, 2026 |
About SLN
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN3... [Read more]
Financial Performance
In 2025, Silence Therapeutics's revenue was $559,000, a decrease of -98.71% compared to the previous year's $43.26 million. Losses were -$88.61 million, 95.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SLN stock is "Hold." The 12-month stock price target is $19.75, which is a decrease of -0.15% from the latest price.
News
Silence Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio downgraded Silence Therapeutics (SLN) to Neutral from Buy with a price target of $20, down from $75, to reflect the proposed acquisition by Merck KGaA.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)
BALA CYNWYD, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Silence Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies downgraded Silence Therapeutics (SLN) to Hold from Buy with a price target of $20, down from $35, after Merck KGaA (MKGAY) announced plans to acquire the company for $20…
Why Merck KGaA Is Paying a 130% Premium for This Gene-Silencing Tech
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.
Silence Therapeutics downgraded to Market Perform from Outperform at William Blair
William Blair analyst Myles Minter downgraded Silence Therapeutics (SLN) to Market Perform from Outperform after the company announced it has entered into an agreement with Merck KGaA (MKGAY) for $20…
Why Is Silence Therapeutics (SLN) Stock Up 125% Today?
Silence Therapeutics stock soared 125.69% on Monday following a $1.3 billion acquisition offer from Merck KGaA.
Silence Therapeutics downgraded to Neutral from Buy at Chardan
Chardan downgraded Silence Therapeutics (SLN) to Neutral from Buy with a price target of $20, down from $27, after the company entered into an agreement to be acquired by Merck…
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target's closing price as of Friday.
Silence Therapeutics tp be acquired by Merck KGaA for $20.00 per ADS in cash
Silence Therapeutics (SLN) has entered into a definitive agreement with Merck KGaA (MKGAY), Darmstadt, Germany, pursuant to which Merck KGaA, Darmstadt, Germany has agreed to acquire Silence in an all...
Merck KGaA to acquire Silence Therapeutics for $20 per ADS in cash
08:01 EDT Merck KGaA (MKGAY) to acquire Silence Therapeutics (SLN) for $20 per ADS in cash
Merck KGaA to acquire Silence Therapeutics for $20 per ADS in cash
Merck KGaA (MKGAY) announced its entry into a definitive agreement to acquire Silence Therapeutics plc (SLN). The purchase price of $20 per ADS in cash, with each ADS representing three…
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive agreement to acquire Silence Therapeutics plc...
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a biotechnology company developing precision engineered medicines using its proprietary siRNA tech...
Silence Therapeutics Proxy statement: Proxy filing
Silence Therapeutics filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Silence Therapeutics Proxy statement: Proxy filing
Silence Therapeutics filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Silence Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A clinical-stage biotech highlighted strong phase II results for its siRNA therapy divesiran in polycythemia vera, showing high efficacy, durable quarterly dosing, and a favorable safety profile. Regulatory and commercial preparations for phase III are underway, with a robust pipeline and CEO search ongoing.
Silence Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Proprietary siRNA platform advances a robust pipeline, highlighted by divesiran's strong phase II results in PV, with quarterly dosing moving to phase III. Full data and regulatory milestones are upcoming, while the pipeline expands into rare and cardiometabolic diseases.
Silence Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The session highlighted advances in siRNA technology, with divesiran showing robust phase II efficacy and a favorable safety profile in PV. Plans are underway for a rapid phase III launch, supported by recent funding, with additional indications and commercial partnerships under evaluation.
Silence Therapeutics Slides: Corporate presentation
Silence Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Silence Therapeutics to Participate in Three September Investor Conferences
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today ...
Silence Therapeutics 13M share Secondary priced at $13.50
Jefferies, Morgan Stanley, Cantor Fitzgerald and William Blair acted as joint book running managers for the offering.
Silence Therapeutics 13M share Secondary priced at $13.50
Jefferies, Morgan Stanley, Cantor Fitzgerald and William Blair acted as joint book running managers for the offering.
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interferin...
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”)...
Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Silence Therapeutics (SLN) to $32 from $25 and keeps an Overweight rating on the shares. Topline Phase 2 results for divesiran in…